## Cheol-Kyu Park

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1773420/cheol-kyu-park-publications-by-year.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44 338 12 16 g-index

52 442 3.4 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
44	First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea <i>Anticancer Research</i> , <b>2022</b> , 42, 1615-1622	2.3	O
43	Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer Patients. <i>Tuberculosis and Respiratory Diseases</i> , <b>2021</b> , 84, 105-114	3.2	
42	Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1598-1604	3.2	1
41	Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG) <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9072-9072	2.2	
40	Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 444-452	3.2	1
39	A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1. <i>Cancer Research and Treatment</i> , <b>2021</b> , 53, 93-103	5.2	1
38	Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study). <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1264-1268	3.2	1
37	Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea. <i>Cancer Medicine</i> , <b>2021</b> , 10, 5809-5822	4.8	3
36	Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors. <i>Immune Network</i> , <b>2020</b> , 20, e27	6.1	15
35	Risk factors for primary lung cancer among never-smoking women in South Korea: a retrospective nationwide population-based cohort study. <i>Korean Journal of Internal Medicine</i> , <b>2020</b> , 35, 692-702	2.5	1
34	Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 408-414	3.2	4
33	Potentially fatal complications of systemic air embolism after computed tomography-guided transthoracic needle biopsy in lung cancer harboring epithelial growth factor receptor mutation: A case report. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 3401-3406	3.2	О
32	Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1585-1590	4.4	5
31	Artificial intelligence and lung cancer treatment decision: agreement with recommendation of multidisciplinary tumor board. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 507-514	4.4	13
30	Superior vena cava syndrome with extensive collateral vessels. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2322	3.2	
29	Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2045-2049	3.2	7
28	Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 942-949	3.2	4

## (2016-2019)

27	Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression. <i>Tuberculosis and Respiratory Diseases</i> , <b>2019</b> , 82, 227-233	3.2	6	
26	A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. <i>Cancer Research and Treatment</i> , <b>2019</b> , 51, 777-787	5.2	26	
25	A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer. <i>Oncology</i> , <b>2018</b> , 94, 373-382	3.6	4	
24	Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report. <i>Journal of Korean Medical Science</i> , <b>2018</b> , 33, e7	4.7	7	
23	Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e775-e781	4.9	17	
22	Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer. <i>Journal of Korean Medical Science</i> , <b>2018</b> , 33, e342	4.7	4	
21	Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 856-864	3.2	16	
20	Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, e289-e296	4.9	15	
19	Review of Sarcoidosis in a Province of South Korea from 1996 to 2014. <i>Tuberculosis and Respiratory Diseases</i> , <b>2017</b> , 80, 291-295	3.2	3	
18	Clinical factors associated with weaning failure in patients requiring prolonged mechanical ventilation. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, 143-150	2.6	12	
17	Acute respiratory distress syndrome and chemical burns after exposure to chlorine-containing bleach: a case report. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, E17-E20	2.6	7	
16	Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study. <i>Journal of Korean Medical Science</i> , <b>2016</b> , 31, 1914-1921	4.7	2	
15	Predictors of Default from Treatment for Tuberculosis: a Single Center Case-Control Study in Korea. <i>Journal of Korean Medical Science</i> , <b>2016</b> , 31, 254-60	4.7	11	
14	Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer. Journal of Thoracic Disease, <b>2016</b> , 8, 2530-2537	2.6	16	
13	Different characteristics associated with intensive care unit transfer from the medical ward between patients with acute exacerbations of chronic obstructive pulmonary disease with and without pneumonia. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, 1121-31	2.6	2	
12	Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. <i>BMC Cancer</i> , <b>2016</b> , 16, 690	4.8	11	
11	Microbiological Characteristics and Predictive Factors for Mortality in Pleural Infection: A Single-Center Cohort Study in Korea. <i>PLoS ONE</i> , <b>2016</b> , 11, e0161280	3.7	12	
10	Endobronchial amyloidosis mimicking bronchial asthma: a case report and review of the literature.  Open Medicine (Poland), 2016, 11, 174-177	2.2	4	

9	Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response. <i>Thoracic Cancer</i> , <b>2016</b> , 7, 639-647	3.2	5
8	Pulmonary sclerosing pneumocytoma mimicking lung cancer: Case report and review of the literature. <i>Thoracic Cancer</i> , <b>2016</b> , 7, 508-11	3.2	12
7	Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 224-6	3.2	О
6	Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 800-4	3.2	21
5	Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , <b>2015</b> , 47, 661-9	5.2	19
4	Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease. <i>Tuberculosis and Respiratory Diseases</i> , <b>2014</b> , 77, 161-6	3.2	12
3	Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2014</b> , 5, 525-9	3.2	1
2	Development of antisynthetase syndrome in a patient with rheumatoid arthritis. <i>Rheumatology International</i> , <b>2011</b> , 31, 529-32	3.6	15
1	Inverse association of peripheral blood CD4(+) invariant natural killer T cells with atopy in human asthma. <i>Human Immunology</i> , <b>2010</b> , 71, 186-91	2.3	14